Cause-specific standardized mortality ratios and 95% confidence interval by sex and cancer diagnosis
. | Subsequent cancer . | . | Cardiac dysfunction . | . | Pulmonary compromise . | . | External causes . | . | Primary disease . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | |||||
| All cases; N = 251* | 62 | 12.0 (9.2-15.2) | 6 | 1.6 (0.6-3.2) | 5 | 5.6 (1.8-11.6) | 3 | 1.2 (0.2-2.9) | 140 | 27.2 (22.9-31.9) | |||||
| Sex | |||||||||||||||
| Male; n = 154 | 38 | 11.2 (7.9-15.9) | 2 | 0.6 (0.1-1.8) | 4 | 6.7 (1.7-14.9) | 2 | 0.9 (0.1-2.5) | 85 | 25.4 (20.3-31.1) | |||||
| Female; n = 97 | 24 | 12.5 (8.0-18.0) | 4 | 4.4 (1.1-9.8) | 1 | 3.1 (0-12.3) | 1 | 2.0 (0-7.9) | 55 | 28.5 (21.5-36.5) | |||||
| Diagnosis | |||||||||||||||
| Acute myeloid leukemia; n = 24 | 9 | 8.3 (3.8-14.6) | 0 | — | 0 | — | 0 | — | 12 | 334.4 (172.0-550.4) | |||||
| Acute lymphoblastic leukemia; n = 24 | 4 | 39.3 (10.2-87.2) | 0 | — | 1 | 50.8 (0-199.3) | 0 | — | 18 | 2521.7 (1491.3-3821.2) | |||||
| Non-Hodgkin lymphoma; n = 112 | 30 | 9.0 (6.0-12.4) | 4 | 1.7 (0.4-3.7) | 1 | 1.7 (0-6.7) | 3 | 2.8 (0.5-6.8) | 55 | 182.6 (137.5-234.0) | |||||
| Hodgkin disease; n = 91 | 19 | 30.1 (18.1-45.2) | 2 | 4.3 (0.4-12.3) | 3 | 29.1 (5.5-71.5) | 0 | — | 55 | 9432.7 (7104.5-12090.3) | |||||
. | Subsequent cancer . | . | Cardiac dysfunction . | . | Pulmonary compromise . | . | External causes . | . | Primary disease . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | No. . | SMR (95% CI) . | |||||
| All cases; N = 251* | 62 | 12.0 (9.2-15.2) | 6 | 1.6 (0.6-3.2) | 5 | 5.6 (1.8-11.6) | 3 | 1.2 (0.2-2.9) | 140 | 27.2 (22.9-31.9) | |||||
| Sex | |||||||||||||||
| Male; n = 154 | 38 | 11.2 (7.9-15.9) | 2 | 0.6 (0.1-1.8) | 4 | 6.7 (1.7-14.9) | 2 | 0.9 (0.1-2.5) | 85 | 25.4 (20.3-31.1) | |||||
| Female; n = 97 | 24 | 12.5 (8.0-18.0) | 4 | 4.4 (1.1-9.8) | 1 | 3.1 (0-12.3) | 1 | 2.0 (0-7.9) | 55 | 28.5 (21.5-36.5) | |||||
| Diagnosis | |||||||||||||||
| Acute myeloid leukemia; n = 24 | 9 | 8.3 (3.8-14.6) | 0 | — | 0 | — | 0 | — | 12 | 334.4 (172.0-550.4) | |||||
| Acute lymphoblastic leukemia; n = 24 | 4 | 39.3 (10.2-87.2) | 0 | — | 1 | 50.8 (0-199.3) | 0 | — | 18 | 2521.7 (1491.3-3821.2) | |||||
| Non-Hodgkin lymphoma; n = 112 | 30 | 9.0 (6.0-12.4) | 4 | 1.7 (0.4-3.7) | 1 | 1.7 (0-6.7) | 3 | 2.8 (0.5-6.8) | 55 | 182.6 (137.5-234.0) | |||||
| Hodgkin disease; n = 91 | 19 | 30.1 (18.1-45.2) | 2 | 4.3 (0.4-12.3) | 3 | 29.1 (5.5-71.5) | 0 | — | 55 | 9432.7 (7104.5-12090.3) | |||||
SMR indicates standardized mortality ratio; 95% CI, 95% confidence interval.
The second malignancies presented here do not add up to 251. The remaining 35 deaths were due to other treatment-related sequelae (infection, liver, and other treatment-related causes)